CMPX - NASDAQ
Compass Therapeutics, Inc.
$2.13
+2.4%Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotCompass Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Compass Therapeutics, Inc. Balance Sheet
CMPX • NASDAQ
| Compass Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
30.6M | 43.5M | 24.2M | 34.9M | 144.5M | 47.1M | 25.3M | 57.5M | |
178.3M | 83.2M | 128.2M | 151.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
208.9M | 126.7M | 152.5M | 186.6M | 144.5M | 47.1M | 25.3M | 57.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 2.6M | 3.1M | 935K | 0.0 | |
913K | 6M | 1.4M | 8.2M | 0.0 | 0.0 | 0.0 | 1.4M | |
209.8M | 132.8M | 153.9M | 194.8M | 147.1M | 50.2M | 26.2M | 58.9M | |
NON-CURRENT ASSETS | ||||||||
9.2M | 7.1M | 2.7M | 4.5M | 6.3M | 1.1M | 3.8M | 5.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 262K | |
568K | 568K | 320K | 320K | 320K | 583K | 392K | 115K | |
9.8M | 7.7M | 3M | 4.9M | 6.7M | 1.7M | 4.1M | 5.7M | |
219.6M | 140.4M | 156.9M | 199.6M | 153.8M | 51.9M | 30.4M | 64.6M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
1.6M | 2.2M | 4.1M | 3.4M | 867K | 1.1M | 1.2M | 0.0 | |
1.6M | 2.2M | 4.1M | 3.4M | 867K | 1.1M | 629K | 1.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 554K | 0.0 | |
0.0 | 3.5M | 576K | 10.1M | 7.2M | 595K | 809K | 0.0 | |
1M | 0.0 | 0.0 | 0.0 | 0.0 | 7.5M | 5.6M | 3.7M | |
0.0 | 338K | 1.2M | 1.1M | 989K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 554K | 519K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 519K | |
11.4M | 2.8M | 1.9M | 1.6M | 1.6M | 976K | 2.3M | 2.5M | |
14M | 8.9M | 7.8M | 16.2M | 10.6M | 10.1M | 9.8M | 8.5M | |
NON-CURRENT LIABILITIES | ||||||||
8.8M | 0.0 | 0.0 | 0.0 | 0.0 | 1.9M | 9.3M | 11.1M | |
0.0 | 1K | 0.0 | 0.0 | 0.0 | 0.0 | 129.9M | 129.9M | |
8.8M | 6.3M | 536K | 1.8M | 3M | 1.9M | 139.2M | 140.9M | |
0.0 | 6.6M | 1.7M | 2.9M | 4M | 0.0 | 0.0 | 0.0 | |
22.8M | 15.2M | 8.3M | 18M | 13.7M | 12M | 149M | 149.4M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 129.9M | |
18K | 13K | 13K | 13K | 10K | 5K | 1K | 2.4M | |
0.0 | 489.7M | 463.8M | 454.7M | 373.7M | 191.3M | 3.3M | 0.0 | |
-431.2M | -364.7M | -315.3M | -272.8M | -233.6M | -151.4M | -121.9M | -87.2M | |
280K | 210K | 37K | -302K | 0.0 | 0.0 | 0.0 | -4.1M | |
627.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -125.8M | |
196.8M | 125.2M | 148.5M | 181.6M | 140.1M | 39.9M | -118.6M | -84.8M | |
196.8M | 125.2M | 148.5M | 181.6M | 140.1M | 39.9M | -118.6M | -84.8M | |
SUMMARY | ||||||||
219.6M | 140.4M | 156.9M | 199.6M | 153.8M | 51.9M | 30.4M | 64.6M | |
178.3M | 83.2M | 128.2M | 151.7M | 0.0 | 0.0 | 0.0 | 262K | |
9.8M | 6.6M | 1.7M | 2.9M | 4M | 9.3M | 14.9M | 14.8M | |
-20.8M | -36.8M | -22.5M | -32M | -140.5M | -37.7M | -10.4M | -42.8M | |
138,286,301 | 138,286,301 | 138,286,301 | 138,286,301 | 138,286,301 | 138,286,301 | 138,286,301 | 138,286,301 |
SEC Filings
CMPX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 | |
S-3 S-3 N/A | December 30, 2025 | December 30, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 |
Related Guides
Continue your CMPX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.